Cambridge Investment Research Advisors, Inc. Durect Corp Transaction History

Cambridge Investment Research Advisors, Inc.

$29.4 Billion
Q3 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 13, 2022	SELL	$0.38 - $0.64 $2,360 - $3,975	-6,212 Reduced 5.0%	118,088 $56,000
Q1 2022 May 12, 2022	SELL	$0.55 - $0.98 $9,900 - $17,640	-18,000 Reduced 12.65%	124,300 $83,000
Q4 2021 Feb 03, 2022	SELL	$0.9 - $1.31 $3,600 - $5,240	-4,000 Reduced 2.73%	142,300 $140,000
Q3 2021 Nov 02, 2021	BUY	$1.21 - $1.61 $6,050 - $8,050	5,000 Added 3.54%	146,300 $187,000
Q2 2021 Aug 10, 2021	SELL	$1.6 - $2.02 $30,400 - $38,380	-19,000 Reduced 11.85%	141,300 $230,000
Q1 2021 May 07, 2021	BUY	$1.86 - $2.87 $298,158 - $460,061	160,300 New	160,300 $317,000

Others Institutions Holding DRRX

# of Institutions

Shares Held

593K

Call Options Held

Put Options Held

View Full List

About DURECT CORP

Ticker DRRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 227,794,000
Market Cap $230M
Description
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogeno...

More about DRRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account